You are here: Home

 Welcome to Elite Pharmaceuticals

 
 

Elite Pharmaceuticals, Inc. specializes in the development of oral controlled release products, such as delayed, sustained, targeted and pulsatile release tablets, pellets, capsules, granules and powders.  The Company’s primary focus is in the therapeutic areas of pain management, allergy, cardiovascular and infection.

 
    The Rodman & Renshaw 16th Annual Global Investment Conference

Live presentation on September. 9, 2014 at 2:55 PM Eastern
replay available until December 18, 2014
View Webcast  

 


Recent Press Releases:
9/9/2014 ELITE PHARMACEUTICALS RELEASES POSITIVE TOP LINE HUMAN ABUSE LIABILITY DATA FOR ELI-200, AN OPIOID ABUSE DETERRENT PRODUCT
HAL study compared subjective effects of drug liking, drug high and good drug effects between ELI-200 and the comparator formulation in non-dependent recreational drug users


9/3/2014 ELITE PHARMACEUTICALS TO PRESENT AT THE 16TH ANNUAL RODMAN & RENSHAW GLOBAL INVESTMENT CONFERENCE IN NEW YORK CITY SEPTEMBER 8-10TH

8/14/2014 Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2015 Revenues Increase by 61%, Product Development on Schedule Conference Call Scheduled for Monday, August 18th at 11:00 AM EDT

8/13/2014 Elite Pharmaceuticals, Inc. to Host Quarterly Business Update Call on August 18, 2014 ….First Quarter Financials for Fiscal Year 2015 Are Scheduled To Be Filed on Thursday, August 14, 2014

7/15/2014 Elite Pharmaceuticals Initiates Pivotal Bioequivalence Study for ELI-201

 

Elite Pharmaceuticals, Inc. 165 Ludlow Ave., Northvale, NJ 07647    Phone:  201-750-2646  Fax:  201-750-2755 
E Mail:  webmaster@elitepharma.com